Pretarsal blepharospasm: Clinical and electromyographic characteristics.


Journal

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
ISSN: 1872-8952
Titre abrégé: Clin Neurophysiol
Pays: Netherlands
ID NLM: 100883319

Informations de publication

Date de publication:
07 2020
Historique:
received: 07 08 2019
revised: 11 03 2020
accepted: 20 03 2020
pubmed: 14 4 2020
medline: 11 5 2021
entrez: 14 4 2020
Statut: ppublish

Résumé

To describe the clinical and electromyographic characteristics of blepharospasm caused by selective involvement of the pars pretarsalis of the orbicularis oculi muscle. Clinical assessment and simultaneous electromyographic recordings from levator palpebrae superioris and pars orbitaria and pretarsalis of orbicularis oculi muscles were performed in patients with blepharospasm and primary failure to botulinum toxin injections. Patients with selective abnormal electromyographic activity of the pars pretarsalis of the orbicularis oculi muscle were identified and treated with selective pretarsal injections of botulinum toxin. We found 24 patients with pretarsal blepharospasm confirmed by the electromyographic assessment. All of them were functionally blind. Three clinical-electromyographic patterns were identified: (a) Impairment of eyelid opening; (b) Increased blinking; (c) Spasms of eye closure combined with varying degrees of excessive blinking and impairment of eye-opening. Pretarsal injections of botulinum toxin induced a significant improvement in all patients and 50 % regained normal or near-normal vision. The clinical improvement was sustained after repeated pretarsal injections. Pretarsal blepharospasm can be suspected on clinical grounds and it can be confirmed by electromyographic recordings. Recognition of this type of blepharospasm is important because of its excellent response to botulinum toxin injections applied into the pretarsal part of the orbicularis oculi muscle.

Identifiants

pubmed: 32280019
pii: S1388-2457(20)30105-X
doi: 10.1016/j.clinph.2020.03.016
pii:
doi:

Substances chimiques

Botulinum Toxins EC 3.4.24.69

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1678-1685

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest F. Grandas received honoraria for lecturing from Allergan S.A. The other authors: none.

Auteurs

Francisco Grandas (F)

Movement Disorders Unit, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain. Electronic address: francisco.grandas@salud.madrid.org.

Alfredo Traba (A)

Clinical Neurophysiology Service, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Javier Ricardo Perez-Sanchez (JR)

Movement Disorders Unit, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Angel Esteban (A)

Clinical Neurophysiology Service, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH